EMA Authorised: Odomzo (sonidegib diphosphate) — Sun Pharmaceutical Industries Europe B.V.

View source ↗

Summary

The European Medicines Agency has authorised Odomzo (sonidegib diphosphate) for basal cell carcinoma, with Sun Pharmaceutical Industries Europe B.V. as the mark…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Odomzo (sonidegib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Basal Cell. MAH: Sun Pharmaceutical Industries Europe B.V.. Decision date: 02/10/2025